Egon Persson
Egon Persson, Akarp SE
Patent application number | Description | Published |
---|---|---|
20100136622 | Method for the Production of Proteins - The present invention relates to a process for the purification of a protease. | 06-03-2010 |
20110081702 | Method for the Production of Proteins - The present invention relates to a process for the purification of a protease. | 04-07-2011 |
Egon Persson, Ballerup DK
Patent application number | Description | Published |
---|---|---|
20090011992 | Human Coagulation Factor VII Polypeptides - The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment. | 01-08-2009 |
20100035814 | N-Terminal Pegylated Prolactin Receptor Molecules - The invention is concerned with N-terminally pegylated polypeptides capable of binding to the prolactin receptor. Such polypeptides may for instance be N-terminally pegylated antagonists of the prolactin receptor, such as for instance prolactin variants. | 02-11-2010 |
20100197597 | Coagulation Factor VII Polypeptides - The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment. | 08-05-2010 |
20120321607 | Factor VII Fusion Polypeptides - The present invention relates to a Factor VII (FVII) fusion polypeptide with a prolonged half-life, wherein the FVII polypeptide can be activated or is in the activated form. | 12-20-2012 |
Egon Persson, Malmo SE
Patent application number | Description | Published |
---|---|---|
20080318276 | Human Coagulation Factor VII Variants - The invention concerns novel coagulation factor VII variants, wherein the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; with the proviso that the variant is not FVII(Ala305). | 12-25-2008 |
20090104661 | Human Coagulation Factor VII Polypeptides - The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment. | 04-23-2009 |
20100158891 | Human Coagulation Factor VII Variants - The present invention encompasses isolated human coagulation Factor VII variants comprising a substitution of Phe in position 374 of SEQ ID NO 1 with another amino acid residue. | 06-24-2010 |